Please wait while the formulary information is being retrieved.
OCREVUS (OCRELIZUMAB)
- Primary progressive multiple sclerosis
- Relapsing form of multiple sclerosis
- Secondary progressive multiple sclerosis
30 mg/mL intravenous solution
- Infuse 600 mg over at least 3.5 hour(s) by intravenous route every 6 months (maximum infusion rate 200 ml/hr)
Primary progressive multiple sclerosis
- Infuse 300 mg over at least 2.5 hour(s) by intravenous route every 2 weeks for 2 doses (maximum infusion rate 180 ml/hr)
- Infuse 600 mg over at least 3.5 hour(s) by intravenous route every 6 months (maximum infusion rate 200 ml/hr)
Relapsing form of multiple sclerosis
- Infuse 300 mg over at least 2.5 hour(s) by intravenous route every 2 weeks for 2 doses (maximum infusion rate 180 ml/hr)
- Infuse 600 mg over at least 3.5 hour(s) by intravenous route every 6 months (maximum infusion rate 200 ml/hr)
Secondary progressive multiple sclerosis
- Infuse 300 mg over at least 2.5 hour(s) by intravenous route every 2 weeks for 2 doses (maximum infusion rate 180 ml/hr)
- Infuse 600 mg over at least 3.5 hour(s) by intravenous route every 6 months (maximum infusion rate 200 ml/hr)
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Progressive multifocal leukoencephalopathy
- Reactivation of hepatitis B
- Viral hepatitis B
Contraindicated
- Carcinoma of breast
- Hepatitis B carrier
- Hepatitis B immune due to latent hepatitis B infection
- Immunosuppression
- Pregnancy
- Severe infection
Severe
Moderate
- Family history of malignant tumor of breast
OCREVUS (OCRELIZUMAB)
- Primary progressive multiple sclerosis
- Relapsing form of multiple sclerosis
- Secondary progressive multiple sclerosis
- Bronchospastic pulmonary disease
- Hypersensitivity drug reaction
- Hypotension
- Immunosuppression
- Pharyngeal edema
- Dizziness
- Dyspnea
- Erythema
- Fatigue
- Fever
- Flushing
- Headache disorder
- Nausea
- Pain in oropharynx
- Pharyngitis
- Pruritus of skin
- Skin rash
- Tachycardia
- Upper respiratory infection
- Urticaria
More Frequent
Severe
Less Severe
- Herpes simplex infection
- Infection
- Lower respiratory infection
- Neutropenic disorder
- Back pain
- Cough
- Depression
- Diarrhea
- Pain
- Peripheral edema
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Neoplasm of breast
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Ocrelizumab
No established safety and efficacy in pediatrics.
- 1 Day – 18 Years
- No established safety and efficacy in pediatrics.
Ocrelizumab
- Severity Level:
D
- Additional Notes: Based on drug pharmacology, b cell depletion is likely to occur in the fetus.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Ocrelizumab
Insufficient data available; human igg present in breast milk
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available; human igg present in breast milk |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Primary progressive multiple sclerosis | |
| G35 | Multiple sclerosis |
| Relapsing form of multiple sclerosis | |
| G35 | Multiple sclerosis |
| Secondary progressive multiple sclerosis | |
| G35 | Multiple sclerosis |
| 0-9 | A-Z |
|---|---|
| G35 | Multiple sclerosis |
| G35 | Multiple sclerosis |
| G35 | Multiple sclerosis |
Formulary Reference Tool